Vor Biopharma Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jean-Paul Kress

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data

Dec 18

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Oct 11

CEO

Jean-Paul Kress (60 yo)

less than a year

Görev süresi

Dr. Jean-Paul Kress, M.D., is Chairman & Chief Executive Officer of Vor Biopharma Inc. from June 25, 2025. Dr. Kress is Independent Director of Sanofi from January 1, 2025. Dr. Kress had been the Chief Exe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Ang	Strategic Advisor	less than a year	US$2.22m	0.012% $ 106.1k
Jean-Paul Kress	Chairman & CEO	less than a year	Veri yok	Veri yok
Siddhartha Mukherjee	Scientific Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Sandesh Mahatme	Chief Business Officer & CFO	less than a year	Veri yok	Veri yok
Adi Osovsky	General Counsel	less than a year	Veri yok	Veri yok
Carol Lincoln	Head of Human Resources	no data	Veri yok	Veri yok
Dallan Murray	Chief Commercial Officer	less than a year	Veri yok	Veri yok
Navid Khan	Chief Medical Affairs Officer	less than a year	Veri yok	Veri yok
Jeremy Sokolove	Chief Medical Officer	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: VOR 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Paul Kress	Chairman & CEO	less than a year	Veri yok	Veri yok
Siddhartha Mukherjee	Scientific Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Malcolm Brenner	Scientific Advisor	3.2yrs	Veri yok	Veri yok
Eric Sievers	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Daniella Beckman	Lead Independent Director	5.8yrs	US$94.80k	Veri yok
Olivier Danos	Scientific & Clinical Advisor	4.5yrs	Veri yok	Veri yok
Steven Devine	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Robert Soiffer	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Alexander Cumbo	Director	less than a year	Veri yok	0% $ 0
Hans-Peter Kiem	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Fouad Namouni	Independent Director	1.9yrs	US$140.50k	0% $ 0
Soheil Meshinchi	Scientific & Clinical Advisor	5.3yrs	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VOR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/19 01:56
Gün Sonu Hisse Fiyatı	2026/04/17 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Vor Biopharma Inc. 12 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jack Allen	Baird
Carter Gould	Barclays
Justin Walsh	B. Riley Securities, Inc.

Vor Biopharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vor Biopharma Inc. Announces Separation of Qing Zuraw as Chief Development Officer, Effective December 31, 2025

Less than half of directors are independent

Vor Biopharma Inc Announces Board Appointments

Vor Bio Appoints Jeremy Sokolove as Chief Medical Officer

Vor Biopharma Appoints Navid Z. Khan as Chief Medical Affairs Officer

Vor Biopharma Inc. Announces Board Changes

Recent updates

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Vor Biopharma Inc. announced that it expects to receive $74.999996 million in funding from TCG Crossover Management, LLC

Vor Biopharma Inc. Announces Separation of Qing Zuraw as Chief Development Officer, Effective December 31, 2025

Less than half of directors are independent

Vor Biopharma Inc Announces Board Appointments

Price target decreased by 11% to US$43.25

Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data

Vor Biopharma Inc. announced that it expects to receive $149.999906 million in funding from RA Capital Management, L.P., Forbion Capital Partners B.V., Caligan Partners, LP, Logos Capital LLC, Frazier Life Sciences Management, LP

Vor Biopharma Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Vor Biopharma Inc. Achieves Primary Endpoint of Reducing Proteinuria in Stage A of A Phase 3 Clinical Study for Iga Nephropathy in China

Vor Bio Appoints Jeremy Sokolove as Chief Medical Officer

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Vor Biopharma Inc. Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Vor Biopharma Inc.'s (NASDAQ:VOR) Intrinsic Value Is Potentially 55% Above Its Share Price

Now 25% undervalued after recent price drop

Vor Biopharma Appoints Navid Z. Khan as Chief Medical Affairs Officer

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Biopharma Inc. Announces Board Changes

Now 22% undervalued

New major risk - Negative shareholders equity

Now 21% undervalued

Vor Biopharma Inc. Appoints Dallan Murray as Chief Commercial Officer

Vor Biopharma Inc. Appoints Alexander (Bo) Cumbo and Michel Detheux to Board of Directors, Effective July 16, 2025

Vor Biopharma Inc. Appoints Qing Zuraw as Chief Development Officer

Vor Bio Appoints Sandy Mahatme as Chief Business Officer, Effective July 9, 2025

Strategic Advisor notifies of intention to sell stock

Vor Biopharma Inc. Announces Board Changes, Effective June 25, 2025

Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)

Vor Biopharma Inc. to Report Q1, 2025 Results on May 14, 2025

Vor Biopharma Receives A Notice from the Nasdaq Stock Market

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma Inc. Announces Resignation of Eyal C. Attar as Chief Medical Officer, Effective April 18, 2025

Vor Biopharma Inc., Annual General Meeting, May 22, 2025

New minor risk - Market cap size

New major risk - Financial position

Vor Biopharma: Short On Cash, Too Much Uncertainty For Now

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

New major risk - Shareholder dilution

Vor Bio Appoints Erez Kalir to Its Board of Directors

Vor Biopharma Inc. announced that it has received $55.55 million in funding from RA Capital Management, L.P.

Price target decreased by 11% to US$11.79

Vor Biopharma Inc. announced that it expects to receive $55.55 million in funding

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from Fda Regarding Registrational Trial Design

Price target decreased by 9.5% to US$11.94

Vor Biopharma Inc. Appoints Han Choi as Chief Financial Officer

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

New minor risk - Share price stability

Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg™

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Comp Value Index

Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024

New minor risk - Market cap size

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

New minor risk - Financial position

Vor Bio Appoints Fouad Namouni to its Board of Directors

Vor Biopharma Inc., Annual General Meeting, May 23, 2024

New major risk - Financial position

Insufficient new directors

Vor Bio Doses First AML Patient with VCAR33 (ALLO)

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Price target decreased by 7.2% to US$13.75

New minor risk - Share price stability

Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 19% to US$14.82